feedback

Activity Details

Free CME/AANP
2.5 AMA PRA Category 1 Credits
2.5 AANP Contact Hours
Released: January 31, 2020
Expires: January 30, 2021
2.5 hours to complete

Accredited By


Target Audience

This activity was developed for rheumatologists, dermatologists, primary care physicians, nurse practitioners, physician assistants, and other health care providers who manage patients with psoriatic arthritis (PsA).

Learning Objectives

  • Utilize validated tools to assess psoriatic arthritis (PsA) disease burden and response to treatment
  • Summarize the clinical pharmacology, including mechanism of action, as well as safety and efficacy, of evidence-based medications for PsA
  • Utilize a treat-to-target approach with individualized evidence-based therapy to reduce symptom burden and, when possible, achieve disease remission/low disease activity
  • Identify and implement treatment of comorbidities of PsA in collaboration with the primary care provider

Activity Description

Philip J. Mease, MD, and Alexis R. Ogdie-Beatty, MD, MSCE, review the pathogenesis and a wide spectrum of clinical features, manifestations, and comorbidities of psoriatic arthritis; talk about classification criteria for PsA and different patient-reported and provider-assessed outcome measures; and discuss treatment recommendations and strategies, as well as various types of current and emerging therapies. Finally, they highlight some of the key issues and challenges of the management of PsA through reviewing patient case studies.

Statement of Educational Need

According to the Rochester Epidemiology Project, 250,000 persons in the United States have psoriatic arthritis (PsA). An estimated 80% of patients with PsA suffer progressive joint damage despite the availability of safe, effective medications approved for PsA. As a consequence, patients with PsA generally experience impaired activities of daily living and patient function, health-related quality of life, and a substantial socioeconomic burden. Patients with PsA often experience difficulty bending down to pick up clothes from the floor (26%), dressing (15%), getting in and out of the car (15%), or bathing (12%). Fatigue and psychological morbidity are common as well. Despite experiencing substantial morbidity, many individuals with PsA view available treatment options as equally or more burdensome than the disease itself. Extra-articular complications are common and may affect lungs, heart, skin, eyes, and other organs; anemia is common as well.

The pharmacologic treatment of patients with PsA has evolved over the past decade. Several categories of medications are now approved, including oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitor, interleukin-17 inhibitors, cytotoxic T-lymphocyte-associated protein 4 immunoglobulin, and Janus kinase inhibitor. Within the past 2 years alone, abatacept, ixekizumab, and tofacitinib have been approved for PsA based on safety and efficacy results in phase 3 clinical trials.

Upon receiving a patient with possible PsA in referral, the specialist is tasked with confirming the diagnosis, followed by initiation of evidence-based therapy to induce remission and relieve patient morbidity. Doing so is often complicated by gaps in knowledge and competence.

Faculty

Alexis R. Ogdie-Beatty, MD, MSCE
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic
University of Pennsylvania
Philadelphia, Pennsylvania


Philip J. Mease, MD
Clinical Professor of Medicine
University of Washington
Director
Rheumatology Research
Swedish Medical Center
Seattle, Washington

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.


In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Alexis R. Ogdie-Beatty, MD, MSCE

  • Consultant - AbbVie, Amgen, BMS, Celgene, Corona, Lilly, Novartis, Pfizer, UCB

Clinical area for disclosures above: Psoriatic Arthritis (PsA)

  • Other - Royalties from Novartis to spouse

Philip J. Mease, MD

  • Research Support - AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
    Consultant - AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Speakers Bureau - AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB

Clinical area for disclosures above: Treatment of Rheumatic Disease

The faculty for this activity have disclosed that there will be discussion about the use of products for non–FDA approved indications.

Additional content planners
The following have no significant relationship to disclose:
Emir Hadzic, PhD (medical writer)
Kam A. Newman, MD (peer reviewer)

Annenberg Center for Health Sciences
Charles Willis, Director of Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is accredited for 2.5 contact hours.
Program ID #5803-EM

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Statement of Commercial Support

This activity is supported by an independent educational grant from Pfizer.

Contact Information for Questions about the Activity

For help or questions about this activity please contact Continuing Education: ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Start Activity

Select your specialty

You must select a specialty

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.